[go: up one dir, main page]

NO20091251L - Nikotinisk acetylkolinreseptorsubtype selektive amider av diazabicykloalkaner - Google Patents

Nikotinisk acetylkolinreseptorsubtype selektive amider av diazabicykloalkaner

Info

Publication number
NO20091251L
NO20091251L NO20091251A NO20091251A NO20091251L NO 20091251 L NO20091251 L NO 20091251L NO 20091251 A NO20091251 A NO 20091251A NO 20091251 A NO20091251 A NO 20091251A NO 20091251 L NO20091251 L NO 20091251L
Authority
NO
Norway
Prior art keywords
compounds
effects
diazabicycloalkanes
significant
sns
Prior art date
Application number
NO20091251A
Other languages
English (en)
Inventor
Craig H Miller
Anatoly A Mazurov
Lan Miao
Yun-De Xiao
Philip S Hammond
Srinivisa Rao Akireddy
V Srinivisa Murthy
Regina C Whitaker
Scott R Breining
Matt S Melvin
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of NO20091251L publication Critical patent/NO20091251L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Forbindelser, farmasøytiske preparater omfattende forbindelsene og metoder for fremstilling og anvendelse derav, er beskrevet. Forbindelsene er amidforbindelser som kan fremstilles av visse heteroarylkarboksylsyrer og visse diazabicykloalkaner. Forbindelsene viser selektivitet overfor, og binder seg med høy affinitet til, nevronale nikotiniske reseptorer av <x4p2-subtypen i sentralnervesystemet (SNS). Forbindelsene og preparatene kan anvendes til å behandle og/eller forhindre en rekke tilstander eller lidelser, spesielt SNS-lidelser. Forbindelsene kan: (i) endre antallet nikotinisk kolinerge reseptorer i hjernen til pasienten, (ii) vise nevrobeskyttende effekter, og (iii), når anvendt i effektive mengder, ikke resultere i merkbare uheldige bivirkninger (for eksempel bivirkninger så som betydelig økning av blodtrykk og hjertetakt, betydelige negative effekter på mave-tarm-kanalen og betydelig effekter på skjelettmuskulatur).
NO20091251A 2006-11-02 2009-03-26 Nikotinisk acetylkolinreseptorsubtype selektive amider av diazabicykloalkaner NO20091251L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85607906P 2006-11-02 2006-11-02
PCT/US2007/083330 WO2008057938A1 (en) 2006-11-02 2007-11-01 Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes

Publications (1)

Publication Number Publication Date
NO20091251L true NO20091251L (no) 2009-05-28

Family

ID=39233054

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091251A NO20091251L (no) 2006-11-02 2009-03-26 Nikotinisk acetylkolinreseptorsubtype selektive amider av diazabicykloalkaner

Country Status (32)

Country Link
US (6) US8114889B2 (no)
EP (2) EP2094703B1 (no)
JP (2) JP5539723B2 (no)
KR (2) KR101415705B1 (no)
CN (4) CN102942569B (no)
AR (2) AR063451A1 (no)
AT (2) ATE545646T1 (no)
AU (2) AU2007317433B2 (no)
BR (2) BRPI0717930A2 (no)
CA (1) CA2663925C (no)
CL (1) CL2007003155A1 (no)
CO (1) CO6180435A2 (no)
CY (1) CY1112374T1 (no)
DK (1) DK2094703T3 (no)
ES (2) ES2395212T3 (no)
HR (1) HRP20110570T1 (no)
IL (2) IL197618A (no)
MX (1) MX2009004801A (no)
MY (2) MY145602A (no)
NO (1) NO20091251L (no)
NZ (2) NZ575557A (no)
PE (2) PE20110671A1 (no)
PL (1) PL2094703T3 (no)
PT (1) PT2094703E (no)
RS (1) RS51834B (no)
RU (2) RU2448969C2 (no)
SA (1) SA07280584B1 (no)
SI (1) SI2094703T1 (no)
TW (3) TWI454262B (no)
UA (2) UA106718C2 (no)
UY (1) UY30686A1 (no)
WO (1) WO2008057938A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
CA2716863A1 (en) * 2008-03-05 2009-09-11 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
JP5502076B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規化合物
EP2344496A1 (en) * 2008-09-05 2011-07-20 Targacept Inc. Amides of diazabicyclooctanes and uses thereof
WO2010028011A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
MY160454A (en) 2009-04-30 2017-03-15 Glaxo Group Ltd Oxazole substituted indazoles as pi3-kinase inhibitors
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
HRP20161461T1 (hr) 2009-11-18 2017-01-27 Suven Life Sciences Limited Biciklički spojevi kao ligandi alfa4beta2 nikotinskih acetilakolinskih receptora
EA023293B1 (ru) 2009-12-29 2016-05-31 Сувен Лайф Сайенсиз Лимитед ЛИГАНДЫ НЕЙРОНАЛЬНОГО НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА αβ
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
AU2015238537B2 (en) 2014-03-26 2019-08-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
PT3848028T (pt) 2014-10-20 2024-09-20 Oyster Point Pharma Inc Métodos de tratamento de estados oculares
UA123362C2 (uk) 2015-09-04 2021-03-24 Ф. Хоффманн-Ля Рош Аг Феноксиметильні похідні
CR20180057A (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CR20180072A (es) 2015-09-24 2018-02-26 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de atx
AU2016328535A1 (en) 2015-09-24 2017-11-09 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
KR20180053408A (ko) 2015-09-24 2018-05-21 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서의 신규한 이환형 화합물
DK3439661T3 (da) 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
SG11201908560SA (en) 2017-03-16 2019-10-30 Hoffmann La Roche Heterocyclic compounds useful as dual atx/ca inhibitors
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
DK3448859T3 (da) 2017-03-20 2019-09-23 Forma Therapeutics Inc Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
MX2022003254A (es) 2019-09-19 2022-04-18 Forma Therapeutics Inc Composiciones activadoras de piruvato cinasa r (pkr).
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) * 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
DE69416869T2 (de) * 1993-12-29 1999-07-01 Pfizer Inc., New York, N.Y. Diazabicyclische neurokinin antagonisten
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) * 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
EP1274710B1 (en) * 1999-12-14 2005-02-23 NeuroSearch A/S Novel heteroaryl-diazabicycloalkanes
US6809105B2 (en) * 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MXPA03008109A (es) 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
JP2004532899A (ja) * 2001-07-06 2004-10-28 ニューロサーチ、アクティーゼルスカブ 新規化合物、その製造方法及びその使用方法
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
CN1317280C (zh) * 2003-02-27 2007-05-23 神经研究公司 新的二氮杂双环芳基衍生物
ATE445618T1 (de) * 2003-02-27 2009-10-15 Neurosearch As Neue diazabicyclische arylderivate
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7365193B2 (en) * 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
ES2297727T3 (es) * 2004-06-09 2008-05-01 F. Hoffmann-La Roche Ag Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos.
JP5236944B2 (ja) * 2004-07-22 2013-07-17 カムブァ、アイピー、ヴェンチュァズ、エル、ピー 微生物感染を治療するためのリファマイシン誘導体
BRPI0611439A2 (pt) * 2005-05-13 2010-09-08 Lexicon Pharmaceuticals Inc compostos multicìclicos e métodos para uso dos mesmos
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Also Published As

Publication number Publication date
BRPI0717930A2 (pt) 2011-05-10
TWI454262B (zh) 2014-10-01
MY145602A (en) 2012-03-15
US20120289572A1 (en) 2012-11-15
US8921410B2 (en) 2014-12-30
EP2284171A1 (en) 2011-02-16
CN102838605B (zh) 2017-04-26
BRPI0722387A2 (pt) 2023-02-23
CN102020646A (zh) 2011-04-20
MX2009004801A (es) 2009-07-31
EP2094703B1 (en) 2011-05-11
US20100173932A1 (en) 2010-07-08
UA98944C2 (ru) 2012-07-10
KR20100124356A (ko) 2010-11-26
IL197618A0 (en) 2009-12-24
US9580434B2 (en) 2017-02-28
TWI405763B (zh) 2013-08-21
CO6180435A2 (es) 2010-07-19
US8859609B2 (en) 2014-10-14
CA2663925A1 (en) 2008-05-15
CL2007003155A1 (es) 2008-05-16
CN102942569B (zh) 2015-10-28
TWI404532B (zh) 2013-08-11
JP5739398B2 (ja) 2015-06-24
IL197618A (en) 2013-09-30
CA2663925C (en) 2015-04-21
ATE509022T1 (de) 2011-05-15
DK2094703T3 (da) 2011-08-29
RU2517693C2 (ru) 2014-05-27
WO2008057938A1 (en) 2008-05-15
NZ575557A (en) 2011-01-28
EP2094703A1 (en) 2009-09-02
JP2013056919A (ja) 2013-03-28
JP5539723B2 (ja) 2014-07-02
AU2010219323B2 (en) 2012-05-03
CN101528745A (zh) 2009-09-09
SI2094703T1 (sl) 2011-07-29
CN102942569A (zh) 2013-02-27
US20160039833A1 (en) 2016-02-11
RU2448969C2 (ru) 2012-04-27
IL209026A0 (en) 2011-01-31
ES2395157T3 (es) 2013-02-08
CY1112374T1 (el) 2015-12-09
RS51834B (sr) 2012-02-29
HK1133260A1 (en) 2010-03-19
AR063451A1 (es) 2009-01-28
RU2009120674A (ru) 2010-12-10
TW201114424A (en) 2011-05-01
US20100081683A1 (en) 2010-04-01
US20150080576A1 (en) 2015-03-19
MY156730A (en) 2016-03-15
PE20081441A1 (es) 2008-10-30
ES2395212T3 (es) 2013-02-11
HK1149751A1 (en) 2011-10-14
KR20090074051A (ko) 2009-07-03
ATE545646T1 (de) 2012-03-15
TW200826935A (en) 2008-07-01
AU2007317433A1 (en) 2008-05-15
JP2010509230A (ja) 2010-03-25
AR079840A2 (es) 2012-02-22
HRP20110570T1 (hr) 2011-09-30
KR101415705B1 (ko) 2014-07-04
US8268860B2 (en) 2012-09-18
SA07280584B1 (ar) 2010-11-02
AU2007317433B2 (en) 2012-05-10
PE20110671A1 (es) 2011-10-20
UA106718C2 (uk) 2014-10-10
CN101528745B (zh) 2011-09-14
AU2010219323A1 (en) 2010-09-30
CN102020646B (zh) 2013-11-13
UY30686A1 (es) 2009-08-03
RU2009138600A (ru) 2011-04-27
CN102838605A (zh) 2012-12-26
TW201305176A (zh) 2013-02-01
NZ587847A (en) 2011-09-30
US8114889B2 (en) 2012-02-14
PL2094703T3 (pl) 2011-10-31
PT2094703E (pt) 2011-07-22
EP2284171B1 (en) 2012-02-15
IL209026A (en) 2014-03-31
US20130005789A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
NO20091251L (no) Nikotinisk acetylkolinreseptorsubtype selektive amider av diazabicykloalkaner
WO2004005293A3 (en) N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2007125501A3 (en) Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
WO2005080343A3 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2008050101A3 (en) Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
MY144132A (en) Polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isoproproxypyridin)yl]-4-penten-2-amine
WO2006108965A3 (fr) Antagonistes npy, preparation et utilisations
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
TW200630336A (en) Novel compounds
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MX2009010630A (es) Derivados de azabicicloalcano selectivos de sub-tipo.
WO2008020306A3 (en) Isoindole derivatives
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders
MX2009013197A (es) Derivados terapeuticos de pirazolonaftiridina.
UY30959A1 (es) Subtipo de amidas selectivas de diazabicicloalcanos
NO20084399L (no) Substituerte 1-amino-4-fenyl-dihydroisokinoliner, fremgangsmate for fremstilling derav, anvendelse derav som et medikament, og medikamenter inneholdende dem
WO2006138316A3 (en) Methods for delivering molecules to the central nervous system
ECSP099377A (es) Amidas de diazabicicloalcanos selectivas del subtipo del receptor nicotínico de acetilcolina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application